• Economy
  • Investing
  • Editor’s Pick
  • Stock
Evil Shark Trades
Stock

Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers

by June 28, 2024
by June 28, 2024

The Biden administration on Wednesday said it will impose inflation penalties on 64 prescription drugs for the third quarter of this year, lowering costs for certain older Americans enrolled in Medicare. 

President Joe Biden has made lowering U.S. drug prices a key pillar of his health-care agenda and reelection platform for 2024. A provision of Biden’s Inflation Reduction Act requires drugmakers to pay rebates to Medicare, the federal health program for Americans over age 65, if they hike the price of a medication faster than the rate of inflation. 

It is separate from another provision under the law that allows Medicare to negotiate lower prescription drug prices with manufacturers. On average, Americans pay two to three times more than patients in other developed nations for prescription drugs, according to the Biden administration.

Some patients will pay a lower coinsurance rate for the 64 drugs covered under Wednesday’s announcement, which fall under Medicare Part B, for the period from July 1 to Sept. 30 “since each drug company raised prices faster than the rate of inflation,” according to a release from the administration.

Some Medicare Part B patients may save as much as $4,593 per day if they use those drugs during the quarter, the release added.  

More than 750,000 Medicare patients use the drugs each year, according to the release. The medications treat conditions such as cancer, certain infections and a bone disease called osteoporosis.

“Without the Inflation Reduction Act, seniors were completely exposed to Big Pharma’s price hikes. Not anymore,” Neera Tanden, White House domestic policy advisor, said in the release.

The Centers for Medicare & Medicaid Services plans to send the first invoices to drugmakers in 2025 for the rebates owed to the program.

In December, Biden released a list of 48 prescription drugs that would be subject to inflation penalties during the first quarter of 2024.

This post appeared first on NBC NEWS
0 comment
0
FacebookTwitterPinterestEmail

previous post
Axios omits crucial details about economists who say Trump will destroy the economy
next post
YouTube is dominating the living room, forcing media companies to decide whether it’s friend or foe

You may also like

All major Las Vegas Strip casinos are now...

Columbia Sportswear sues Columbia University, alleging trademark infringement

JPMorgan marks 1,000th branch opening since 2018 expansion...

Apple crushes Wall Street expectations as iPhone sales...

Ontario cancels internet deal with Musk’s Starlink as...

Trump ends de minimis exemption for global low-cost...

Recall warns some Celsius energy drink cans accidentally...

Union Pacific to buy Norfolk in $85 billion...

Things are getting better at Boeing under CEO...

Elon Musk confirms Tesla has signed a $16.5...

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.






    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    Recent Posts

    • LIZ PEEK: Hillary is finally paying dearly for dirty tricks that hurt Trump and American voters
    • All major Las Vegas Strip casinos are now unionized in historic labor victory
    • DOJ launching grand jury investigation into Russiagate conspiracy allegations: sources
    • Trump’s tariff power grab barrels toward Supreme Court
    • GOP memo preps House Republicans to tout Trump’s ‘big, beautiful bill’ as Dems go on offense

    Categories

    • Economy (6,932)
    • Editor's Pick (3,862)
    • Investing (2,826)
    • Stock (1,402)
    Email Whitelisting About Us Terms & Conditions Privacy Policy Contact Us

    Disclaimer: Evilsharktrades.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 EvilSharkTrades.com


    Back To Top
    Evil Shark Trades
    • Economy
    • Investing
    • Editor’s Pick
    • Stock